Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Overview
Clinical Cancer Research is the official journal of the American Association for Cancer Research. It publishes cutting-edge research on all aspects of cancer, including prevention, diagnosis, treatment, and survivorship. With a focus on clinical trials and translational research, this journal provides valuable insights into the latest advancements in cancer care and serves as a vital resource for oncologists, researchers, and healthcare professionals.
Details
Details
Abbr.
Clin Cancer Res
Start
1995
End
Continuing
Frequency
Semimonthly, Aug. 15, 2003-
p-ISSN
1078-0432
e-ISSN
1557-3265
Country
United States
Language
English
Specialty
Oncology
Metrics
Metrics
h-index / Ranks: 93
377
SJR / Ranks: 301
4623
CiteScore / Ranks: 291
21.80
JIF / Ranks: 354
11.5
Recent Articles
11.
Xiong W, Yan Y, Wang T, Sui W, Yu Y, Yu T, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40053705
Purpose: Waldenström macroglobulinemia (WM) is a rare type of lymphoma, with no optimal treatment. BTK inhibitor have shown promising outcomes, yet achieving deep remission (VGPR or CR) remains challenging and...
12.
Morelli E, Ribeiro C, Rodrigues S, Gao C, Socciarelli F, Maisano D, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40053701
Purpose: In multiple myeloma (MM), tumor cells reprogram metabolic pathways to sustain growth and monoclonal immunoglobulin production. This study examines acetyl-CoA carboxylase 1 (ACC1), the enzyme driving the rate-limiting step...
13.
Chumsri S, Larson J, Liu E, Tenner K, Adams D, Weidner M, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40053697
Purpose: Activation of the RAS/MAPK pathway is associated with reduced tumor-infiltrating lymphocytes and poor outcomes in triple-negative breast cancer (TNBC). Previous studies demonstrated that inhibition of the MAPK pathway with...
14.
Tseng I, Chen Y, Ai D, Zhu Z, Zhao W, Fan M, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40053692
Purpose: Preclinical model found that elective nodal irradiation (ENI) attenuated the efficacy of radiotherapy and radio-immunotherapy. However, limited clinical studies have explored the correlation between radiation dose-volume parameters of negative...
15.
Trontzas I, He M, Wurtz A, Robbins C, Robinson N, Bates K, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40047548
Background: Antibody-drug conjugates (ADCs) are a promising approach for the management of patients with non-small cell lung cancer (NSCLC). However, only a small subset of patients derive benefit from these...
16.
Park J, Joung J, Lim M, Lee J, Kim B, Kim J, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40043003
Purpose: This open-label, investigator-initiated, phase II study was conducted to evaluate the safety, survival and neoadjuvant outcomes of NAC combined with dual immune checkpoint inhibitors in advanced-stage EOC. Patients And...
17.
Pal S, Bernard-Tessier A, Grell P, Gao X, Kotecha R, Picus J, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40043000
Background: Mutations or silencing of the von Hippel Lindau (VHL) tumor suppressor gene accumulates hypoxia-inducible factors (HIFs). HIF-2α is implicated in the oncogenesis of ~50% of patients with clear cell...
18.
Zhang W, Li J, Liu H, Wang K, Xiao B, Wang Y, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40036693
Purpose: Neoadjuvant anti-PD-1 immunotherapy combined with chemotherapy has shown promising pathological responses in various cancers, including oral squamous cell carcinoma (OSCC). However, the pathological response of lymph node (LN) metastases...
19.
Patel T, Corneli A, Balcazar P, Lipset C, Calvert S, Mervin-Blake S, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40036170
The COVID-19 pandemic disrupted cancer clinical trials, prompting sponsors to adopt decentralized clinical trial (DCT) elements to ensure patient safety and trial continuity. Supported by FDA emergency guidance, the FDA...
20.
Yuan H, Chen Q, Jiang K, Houchen C, Zhang Y, Li M
Clin Cancer Res
. 2025 Mar;
PMID: 40036010
The shared HLA-bound neoepitopes in pancreatic ductal adenocarcinoma (PDAC) represent a novel class of non-canonical antigens with single amino acid substitutions, resulting from translational errors. These peptides, shared across PDAC...